SPRY News

ARS Pharmaceuticals, Inc. (SPRY) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before October 5, 2026

SPRY SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Levi & Korsinsky Notifies ARS Pharmaceuticals, Inc. (SPRY) Shareholders of Class Action Lawsuit and October 5, 2026 Deadline

Kaplan Fox Alerts Investors of ARS Pharmaceuticals Inc. (SPRY) to a Pending Securities Class Action - Deadline is October 5, 2026 Ready to Announce with Confidence?

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

Securities Fraud Class Action Filed Against ARS Pharmaceuticals, Inc. (SPRY) - Levi & Korsinsky Reminds Investors of October 5, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY

Faruqi & Faruqi, LLP Urges ARS Pharmaceuticals (NASDAQ: SPRY) Investors to Seek Counsel Before the October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action

Investors Urged to Contact Levi & Korsinsky for Information Before October 5, 2026 – ARS Pharmaceuticals, Inc. (SPRY)

Pomerantz LLP Alerts Shareholders to Investor Suit Involving ARS Pharmaceuticals, Inc. – SPRY